IMPORTANCE OF NANOCARRIERS AND PROBIOTICS IN THE TREATMENT OF ULCERATIVE COLITIS

  • VANDANA THAKUR Abhilashi College of Pharmacy, NerChowk,Mandi, Himachal Pradesh, India
  • BHUPENDRA SINGH Abhilashi College of Pharmacy, NerChowk,Mandi, Himachal Pradesh, India
  • ANKITA SHARMA Abhilashi College of Pharmacy, NerChowk,Mandi, Himachal Pradesh, India
  • NISHA KUMARI Abhilashi College of Pharmacy, NerChowk,Mandi, Himachal Pradesh, India
  • INDER KUMAR School of Phrarmacy, Abhilashi University Mandi, Himachal Pradesh, India
  • KRITIKA VERMA School of Phrarmacy, Abhilashi University Mandi, Himachal Pradesh, India
  • ARVIND KUMAR School of Phrarmacy, Abhilashi University Mandi, Himachal Pradesh, India
  • SUSHMITA RANA School of Phrarmacy, Abhilashi University Mandi, Himachal Pradesh, India

Abstract

Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are variable. Ulcerative colitis is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and immune suppressants are used for the therapy of ulcerative colitis. The mainchallenges in the management of thediseaseare drug-related side-effects and local targeting. To overcome these challengesprobiotics and micro and Nanoparticulate systemauspiciousapproaches to overcome drug-related adverse side effects and local targeting.Upon ingestion, the probiotics can result in beneficial health effects. Probiotics and micro and nanoparticulate approaches for suitable targeting and overcome the drug-associated side effect. Probiotics are mainly used as gut modulators but are also nowadays explored for their use in ulcerative colitis.The current therapeutic goals are to achieve clinical remission along with mucosal healing, avoidance of complications such as side effects of the drug and to improve the quality of life. The use of probiotics to increase the health of the intestine and used to block or manage intestinal disorders. They may prevent the induction of inflammatory reactions. Probiotics must be inspected for efficacy in the prevention and management of a wide spectrum of gastrointestinal diseases, like antibiotic-associated diarrhea.Micro and Nanoparticulate drug delivery system has been achieving huge importance for targeting of the drug to colon locally at a controlled and sustained rate.

Keywords: Inflammatory chronic disease, Probiotics, Micro and Nanoparticulate

References

1. Kassam Z, Belga S, Roifman I, Hirota S, Jijon H, Kaplan GG, et al. Inflammatory bowel disease cause-specific mortality: a primer for clinicians. InflammBowel Dis 2014;12:2483-92.
2. Xavier RJ, Podolsky DK. Unraveling the pathogenesis of inflammatory bowel disease. Nature 2007;7:427-34.
3. Larmonier CB, Shehab KW, Ghishan FK, Kiela PR. T lymphocyte dynamics in inflammatory bowel diseases: role of the microbiome. Biomed Res Int 2015;25. https://doi.org/10.1155/2015/504638
4. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World JGastroenterol 2014;1:91.
5. Friend DR. New oral delivery systems for the treatment of inflammatory bowel disease. Adv Drug Delivery Rev2005;2:247-65.
6. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol2015;4:205.
7. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. GastroenterolHepatol2010;5:339.
8. Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology2012;1:46-54.
9. Ungaro R, Chang HL, Cote Daigneaut J, Mehandru S, Atreja A, Colombel JF. Statins associated with decreased risk of new onset inflammatory bowel disease.Am J Gastroenterol 2016;10:1416.
10. Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw 2017;1:25-40.
11. Weinstock JV, Elliott DE.Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 2008;1:128-33.
12. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;5:1-16.
13. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett 2014;2:235-41.
14. Navaneethan U, Jegadeesan R, Gutierrez NG, Venkatesh PG, Hammel JP, Shen B, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J CrohnsColitis 2013;12:684-91.
15. Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease. Am Fam Physician 1998;1:57-68.
16. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest2007;3:514-21.
17. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Gen Intern Med2002;6:475-96.
18. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, FichtnerFeigl S, et al.Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.J Clin Invest 2004;10:1490-7.
19. Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J PhysiolGastr L 1998;1:G203-9.
20. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol2011;7:3204.
21. Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev GastroenterolHepatol 2011;11:646.
22. ArdizzoneS, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. Intern Med J 2002;6:475-96.
23. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc2014;11:1553-63.
24. Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. GastrointestPharmacol 2017;239:115-46.
25. Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5?aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Library2016;5. DOI:10.1002/14651858.CD000544.pub4
26. Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis 2014;3:200-7.
27. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al.Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;4:590.
28. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005;1:3-12.
29. Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013;7:1040.
30. Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. Gastrointestinal Pharmacology 2017;239:115-46.
31. GarudS,Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Ther AdvGastroenterol 2009;2:99-108.
32. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;12:1639-41.
33. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J PediatrGastroenterol Nutr2007;2:265-7.
34. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol2011;27:3204.
35. Kim KK, Pack DW. Microspheres for drug delivery.J Biomed Nanotechnol 2006;2:19-50.
36. Lee JK, Tang DH, Mollon L, Armstrong EP. Cost-effectiveness of biological agents used in ulcerative colitis. Best Pract Res ClinGastroenterol 2013;6:949-60.
37. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J,et al. Infliximab for induction and maintenance therapy for ulcerative colitis.N Engl J Med 2005;23:2462-76.
38. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Loane J, et al. Safety and efficacy of adalimumab (D2E7) in crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;1:75.
39. Sowmaya C, Reddy GS, Neelaboina VP. Colon specific drug delivery systems: A review on pharmaceutical approaches with current trends. Int Res J Pharm2012;7:45-57.
40. Lautenschläger C, Schmidt C, Lehr CM, Fischer D, Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Bipharm 2013;3:578-86.
41. Talaei F, Atyabi F, Azhdarzadeh M, Dinarvand R, Saadatzadeh A. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. Eur J Pharm Sci 2013;4:712-22.
42. Collnot EM, Ali H, Lehr CM. Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Controlled Release 2012;2:235-46.
43. YoushiaJ,Lamprecht A. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases. Expert Opin Drug Delivery2016;2:281-94.
44. Coppi G, Iannuccelli V, Bernabei MT, Cameroni R. Alginate microparticles for enzyme peroral administration. Int J Pharm 2002;2:63-6.
45. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. J Pharm Res Int 2001;6:788-93.
46. Lamprecht AL, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P,et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol ExpTher 2001;2:775-81.
47. Duan H, Lu S, Qin H, Gao C, Bai X, Wei Y, et al. Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis.Int J Pharm 2017;2:214-24.
48. Duan H, Lu S, Gao C, Bai X, Qin H, Wei Y, et al.Mucoadhesivemicroparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon.Colloids Surf B 2016;9:510-9.
49. Mladenovska K, Cruaud O, RichommeP, Belamie E, Raicki RS, VenierJulienne MC, et al. 5-ASA loaded chitosan–Ca–alginate microparticles: preparation and physicochemical characterization. Int J Pharm 2007;2:59-69.
50. Mura C, Nacher A, Merino V, Merino Sanjuan M, Manconi M, Loy G, et al. Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery. Colloids Surf B 2012;6:199-205.
51. Melero A, Draheim C, Hansen S, Giner E, Carreras JJ, TalensVisconti R, et al. Targeted delivery of cyclosporine a by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur J Pharm Bipharm 2017;10:361-71.
52. Guada M, Lana H, Gil AG, del Carmen Dios Vieitez M, Blanco Prieto MJ. Cyclosporine a lipid nanoparticles for oral administration: pharmacodynamics and safety evaluation. Eur J Pharm Bipharm2016;4:112-8.
53. Dai W, Guo Y, Zhang H, Wang X, Zhang Q. Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine a. Int J Pharm 2015;2:718-25.
54. Oosegi T, Onishi H, Machida Y. Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur J Pharm Bipharm 2008;2:260-6.
55. Zhang H, Shahbazi MA, Makila EM, da Silva TH, Reis RL, Salonen JJ, et al. Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine. Biomaterials 2013;12:9210-9.
56. OnOnishi H, Oosegi T, Machida Y. Efficacy and toxicity of eudragit-coated chitosan–succinyl-prednisolone conjugate microspheres using rats with 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis. Int J Pharm 2008;2:296-302.
57. Crcarevska MS, Dodov MG, Goracinova K. Chitosan coated Ca–alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur J Pharm Biopharm 2008;3:565-78.
58. Krishnamachari Y, Madan P, Lin S. Development of pH-and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 2007;2:238-47.
59. Cerchiara T, AbruzzoA, Di Cagno M, Bigucci F, Bauer Brandl A, Parolin C, et al. Chitosan based micro-and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. Eur J Pharm Biopharm 2015;5:112-9.
60. Berthold A, Cremer K, Kreuter J. Collagen microparticles: carriers for glucocorticosteroids. Eur J Pharm Biopharm 1998;1:23-9.
61. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;6:1620-33.
62. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, et al. Health benefits of probiotics: a review. ISRN Nutr2013;1.DOI:10.5402/2013/481651
63. Figueroa Gonzalez I, Cruz Guerrero A, Quijano G. The benefits of probiotics on human health. J Microbial BiochemTechnol S 2011;1:1948-5948.
64. Soccol CR, Vandenberghe LP, Spier MR, Medeiros AB, Yamaguishi CT, Lindner JD, et al.The potential of probiotics: a review. Food Technol Biotech 2010;4:413-34.
65. Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, Li HL, et al.Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol2013;5:1595-606.
66. Adam JK, Odhav B, Naidu K. Probiotics: recent understandings and biomedical applications. Curr Trends Biotechnol Pharm2012;1:1-14
67. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. J ClinNutrMetab 2014;5:761-7.
68. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol 2015;6:81.
69. Anom EY, Udenigwe CC. Novel approaches to enhance the functionality of fermented foods. J FunctFoods2015;269.DOI:10.1002/9781118504956.ch9
70. Hajela N, Ramakrishna BS, Nair GB, Abraham P, Gopalan S, Ganguly NK. Gut microbiome, gut function, and probiotics: Implications for health. Indian JGastroenterol2015;2:93-107.
71. Surono IS, Martono PD, Kameo S, Suradji EW, Koyama H. Effect of probiotic L. plantarum IS-10506 and zinc supplementation on humoral immune response and zinc status of Indonesian pre-school children. J Trace ElemMedBiol 2014;4:465-9.
72. Wen K, Tin C, Wang H, Yang X, Li G, GiriRachman E, et al. Probiotic Lactobacillus rhamnosus GG enhanced Th1 cellular immunity but did not affect antibody responses in a human gut microbiota transplanted neonatal gnotobiotic pig model. PloSOne2014;4:94504.
73. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;11:1617-23.
74. Fábrega MJ, Rodriguez Nogales A,GarridoMesa J,Algieri F, Badia J, Gimenez R, et al.Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coli Nissle 1917 in DSS-experimental colitis in mice. FronMicrobiol 2017;8:1274.
75. Correa NB, PeretFilho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacteriumlactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. JClinGastroenterol2005;5:385-9.
76. KruiKruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;11:1617-23.
77. Fabrega MJ, Rodriguez Nogales A, GarridoMesa J, Algieri F, Badia J, Gimenez R, et al. Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coliNissle 1917 in DSS-experimental colitis in mice. FronMicrobiol2017;8:1274.
78. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Libr 2011;12:CD007443.
79. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. Probiotic administration in patients with ileal pouch–anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.Inflamm Bowel Dis 2008;5:662-8.
80. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment PharmacolTher 2006;11:1567-74.
81. Loren V, Manye J, Fuentes MC, Cabre E, Ojanguren I, Espadaler J. Comparative effect of the I3. 1 probiotic formula in two animal models of colitis. Probiotics AntimicrobProteins 2017;1:71-80.
82. W Wang BG, Xu HB, Xu F, Zeng ZL, Wei H. Efficacy of oral bifidobacteriumbifidumATCC 29521 on microflora and antioxidant in mice. Can J Microbiol 2015;3:249-62.
83. Chauhan R, SudhakaranVasanthakumari A, Panwar H, Mallapa RH, Duary RK, Batish VK, et al. Amelioration of colitis in the mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentumLf1. BioMed Res Int2014;1:206732.
Statistics
57 Views | 18 Downloads
Citations
How to Cite
THAKUR, V., SINGH, B., SHARMA, A., KUMARI, N., KUMAR, I., VERMA, K., KUMAR, A., & RANA, S. (2021). IMPORTANCE OF NANOCARRIERS AND PROBIOTICS IN THE TREATMENT OF ULCERATIVE COLITIS. International Journal of Applied Pharmaceutics, 13(1), 77-85. https://doi.org/10.22159/ijap.2021v13i1.37510
Section
Review Article(s)